19.09.2007 11:00:00
|
CommonHealth Consumer Group Launches EvoLogue
CommonHealth Consumer Group (CCG) today announced the launch of
EvoLogue, a full-service consumer agency that will provide
insight-driven behavioral- marketing services to help improve the
dialogue between consumers and healthcare professionals.
CCG is part of CommonHealth (www.commonhealth.com),
the world’s leading healthcare-communications
network and a WPP (NASDAQ/ADR: WPPGY; www.wpp.com)
company.
The EvoLogue name "is a synthesis of the words ‘evolving’
and ‘dialogue,’”
said Meg Columbia-Walsh, managing partner and president of CCG, EvoLogue
and eBusiness. "The name reflects our belief
in the centrality of the healthcare professional-consumer dialogue to
improving compliance, persistency and outcomes with both prescription
and over-the-counter brands. And it conveys our commitment to providing
superior strategic, multichannel communications, including advertising,
CRM, interactive and proprietary behavioral-marketing services.”
At the heart of the EvoLogue offering are methodologies developed at
CommonHealth that provide deep insight into the healthcare-consumer
experience. EvoLogue uses these reality-based insights, many drawn from
actual exam-room conversations, to create behavioral-marketing
communications that "reflect consumers’
actual experiences so they are more emotionally and practically relevant
to their needs,” Ms. Columbia-Walsh said.
Chief among those needs is for the consumer to adequately tell his or
her health "story”
in the time-pressured environment of the typical office visit. Right
now, Ms. Columbia-Walsh noted, "patients fail
to tell their physicians how new conditions or symptoms impact their
lives. Doctors often don’t ask open-ended
questions or probe for lifestyle impact. And patients tend to leave
their issues of greatest concern to the end of the visit. That means
that the most critical part of the doctor-patient dialogue often takes
place with the doctor’s hand on the knob of
the half-open door,” she continued.
"Is it any wonder that these ‘doorknob’
conversations so often fail to elicit the desired behaviors and
outcomes? The true wonder may be that they succeed as often as they do.
We can do better, and we have to—for the sake
of patient health, greater in-office efficiencies and the health of our
clients’ brands.”
EvoLogue staff have deep strategic, healthcare and multichannel
expertise and are drawn from a variety of disciplines—from
general advertising, CRM and interactive to managed care and
professional advertising—the better to deploy
against a particular marketing challenge without prejudice or favor. "It’s
the old adage: ‘When all you have is a
hammer, everything looks like a nail.’
EvoLogue was formed with the specific intent of breaking that paradigm,”
Ms. Columbia-Walsh added.
The EvoLogue brand roster includes significant assignments from
AstraZeneca, Pfizer, Merck, Johnson & Johnson, Novartis and Genentech.
EvoLogue senior staff includes Shelagh Brooke, director of strategic
planning; Mark Robinson, chief operating officer; Mark Kosak and Steve
Pashkoff, co-chief creative officers; and Betsy Alvarez, director of
business development.
Ms. Columbia-Walsh concluded, "If we can
create a common lexicon that allows doctors and patients to communicate
in a kind of shorthand, if we can get both parties past the ‘don’t
ask, don’t tell’
phenomenon so widespread today, we will have accomplished what we set
out to do.”
CommonHealth comprises CommonHealth Consumer Group, EvoLogue, Altum,
Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn,
Ferguson, HLS, MBS/Vox, Noesis, ProCom, Qi and Solara. The organization
also maintains numerous partnerships both within and outside of the WPP
network of companies.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu WPP 2012 PLC (spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu WPP 2012 PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
WPP 2012 PLC (spons. ADRs) | 54,96 | 0,27% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 480,91 | 0,40% |